PAYS

AI MemoPost-earnings T+3

Paysign

As of 2026-05-15/Post-earnings T+3/Confidence medium

Open ticker Back to Memos

Data freshness

AI Memo

As of 2026-05-15 • Model: RankAlpha Sentiment Codex

Decision Panel

Action, confidence, horizon, and decision blockers at a glance.

Action

—

Confidence

medium

Horizon

—

Key catalyst

New $5 million repurchase authorization adds modest capital-allocation support • 2026-12-31

Base target: $7 / p=45% prob

Biggest risk

The post-earnings reaction was mixed because management did not raise the full-year outlook after a strong quarter. Trusted post-print coverage tied the selloff to conservative guidance framing, and low analyst coverage means there is limited external revision support if Q2 operating targets slip.

Invalidation

Break below $5 or thesis failure.

What would change my mind?

Primary-source evidence improved after earnings: Q1 revenue rose 50.8% to $28.04 million, adjusted EBITDA rose 113.4% to $10.59 million, and management reiterated a full-year revenue range of $106.5-$110.5 million with confidence in the upper half. Secondary post-print coverage also showed DA Davidson reiterating Buy with a $9 target after the beat, so the basic growth thesis remains intact despite the pullback.

Research note

Recommendation

—

Confidence

medium

As of

2026-05-15

Base target

p=45%

Bull target

p=30%

Bear target

p=25%

Key bullets

Fast scan of bull, bear, and watch items

BullKey bullets

Q2 exit targets are now the clearest near-term proof point after the Q1 beat
Patient-affordability mix is still the main earnings engine
Primary-source evidence improved after earnings: Q1 revenue rose 50.8% to $28.04 million, adjusted EBITDA rose 113.4% to $10.59 million, and management reiterated a full-year revenue range of $106.5-$110.5 million with confidence in the upper half.

BearKey bullets

Coverage remains sparse for a small-cap name, so analyst revision flow is limited and thesis validation still depends heavily on company-reported execution.
Management reiterated rather than raised full-year 2026 guidance after a strong Q1 beat, which the market treated as a negative signal on May 13, 2026.
Plasma center count exited Q1 at 573 versus 595 at year-end 2025 because 20 centers were sold to companies using a competing provider and two underperforming centers were closed [#8-K-2026-05-12].

WatchKey bullets

New $5 million repurchase authorization adds modest capital-allocation support

Summary

High-level snapshot

Recommendation

Model confidence

medium

Timeframe

Asset

Equity

Trigger

Post-earnings T+3

Base case: $7 (p=45%)

Target spread vs base: +29% / -36%

Scenario probabilities

Bull Target: $9 (p=30%)Base Target: $7 (p=45%)Bear Target: $5 (p=25%)

Commentary

This is still a cautious monitoring-style post-earnings memo rather than a full risk-on upgrade. Primary-source support is good because the view is anchored by the May 12, 2026 earnings release and the May 13, 2026 10-Q, but post-print tape action was mixed: trusted market coverage said the stock fell as much as 27.7% intraday on May 13 before finishing down 12.3% because investors wanted a guidance raise, and the May 14 anchor close was $5.79. Analyst follow-through appears thin so far, with only limited visible revision support, and there is no social-context coverage in the packet to offset that caution.

As of 2026-05-15 • Updated bi-weekly / post-earningsSource: Internal modelMethodology

Analyst Summary

Thesis highlights from the latest analysis

Bull Case

Bear Case

Drivers

Scannable catalysts and supporting factors

Q2 exit targets are now the clearest near-term proof point after the Q1 beat
Patient-affordability mix is still the main earnings engine

Scenarios

Bull Target (Scenario probability)

$9 / p=30% prob

Base Target (Scenario probability)

$7 / p=45% prob

Bear Target (Scenario probability)

$5 / p=25% prob

Analysis 2026-05-15 · RankAlpha Sentiment Codex

Analysis reference price unavailable. Targets are shown without scenario returns.

Sentiment & Exposure

News Sentiment (30d)

58.00

Social Sentiment (7d)

0.00

Events

Other notable items detected

EVENT2026-12-31
New $5 million repurchase authorization adds modest capital-allocation support
The 10-Q disclosed that on May 8, 2026 the board authorized a new stock repurchase program for up to $5 million over 36 months expiring May 7, 2029, after the prior authorization expired in March. The authorization is not the core thesis, but it can support sentiment if cash generation remains healthy and management buys into weakness [#10-Q-2026-05-13].
Prob 57.00% • Move 6.00% • Priced-in 36.00%

Short-term Catalysts

Next few weeks

Q2 exit targets are now the clearest near-term proof point after the Q1 beat
2026-06-30
Paysign's May 12, 2026 earnings release said first-quarter revenue, operating margin, and net income all finished above the high end of prior ranges, while management reiterated full-year guidance and expects to exit the second quarter with 147-150 active patient affordability programs and 555-560 plasma centers. That gives investors a dated operating checkpoint after the market sold off on unchanged full-year guidance [#8-K-2026-05-12].
Prob 68% • Move 14% • Priced-in 58%

Long-term Catalysts

Months to a year

Patient-affordability mix is still the main earnings engine
2026-12-31
The earnings release showed Q1 2026 pharma revenue up 81.9% to $15.68 million, patient affordability at 135 active programs, gross margin up to 65.0%, and operating margin up to 23.8%, while the 10-Q showed pharma growth was driven by new patient-affordability launches and plasma growth was helped by normalized donation trends. If that mix persists, Paysign still has a credible path to the upper half of its full-year framework [#8-K-2026-05-12] [#10-Q-2026-05-13].
Prob 64% • Move 24% • Priced-in 54%

Risks

Coverage remains sparse for a small-cap name, so analyst revision flow is limited and thesis validation still depends heavily on company-reported execution.
Management reiterated rather than raised full-year 2026 guidance after a strong Q1 beat, which the market treated as a negative signal on May 13, 2026.
Plasma center count exited Q1 at 573 versus 595 at year-end 2025 because 20 centers were sold to companies using a competing provider and two underperforming centers were closed [#8-K-2026-05-12].
The balance sheet carries large working-capital balances tied to the operating model, including $94.25 million of accounts receivable and $158.95 million of restricted cash at March 31, 2026, which can complicate cash-conversion optics [#10-Q-2026-05-13].

Peers

Symbol	Summary
GDOT	Green Dot is the closest adjacent public comp for prepaid and stored-value card infrastructure, though it lacks Paysign's healthcare and patient-affordability specialization.
MQ	Marqeta is useful for benchmarking issuing and processing economics, but it is a broader modern-payments platform and only an indirect operating peer for Paysign.

Sources

Internal and external references used in this analysis

Model source: RankAlpha Sentiment Codex
Analysis date: 2026-05-15

Loading AI feed…

Symbol

Summary

GDOT

Green Dot is the closest adjacent public comp for prepaid and stored-value card infrastructure, though it lacks Paysign's healthcare and patient-affordability specialization.

Marqeta is useful for benchmarking issuing and processing economics, but it is a broader modern-payments platform and only an indirect operating peer for Paysign.